First-line Therapy in Metastatic PDAC

NCT ID: NCT03487016

Last Updated: 2022-09-08

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 270 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-02-15
• Study Completion Date: 2023-07-31

Brief Summary

The overarching hypothesis of this trial is that the NAPOLI regimen and alternating cycles of NAPOLI and mFOLFOX6 (seq-NAPOLI-FOLFOX) are superior to the current standard of care gemcitabine/nab-paclitaxel. Furthermore, we propose that the NAPOLI regimen and seq-NAPOLI-FOLFOX display favourable safety profiles and allow for longer first line treatment and higher rate of transition into the second line setting.

Detailed Description

Pancreatic ductal adenocarcinoma (PDAC) remains an almost uniformly lethal disease. Although there has been significant progress in understanding of the underlying molecular biology of pancreatic cancer, this progress has not translated into substantially better outcome.

Alarmingly, the number of pancreatic cancer cases is constantly rising and pancreatic cancer will be the second most frequent cause of cancer related death by 2030.

Accordingly, novel therapeutic strategies for patients with pancreatic cancer are desperately needed.

Recently, the combination of gemcitabine and nab-paclitaxel proofed to be superior when compared to single agent gemcitabine (overall survival [OS] 8.7 months in the nab-paclitaxel/gemcitabine group versus 6.6 months in the gemcitabine group; hazard ratio for death, 0.72; 95% confidence interval [CI], 0.62 to 0.83; P<0.001). Consequently, this combination therapy is now regarded as a standard treatment option for patients with metastatic pancreatic cancer and should therefore serve as control for future clinical studies.

Furthermore, the combination of 5-fluorouracil (5-FU), irinotecan and oxaliplatin (FOLFIRINOX) was found to be more effective in the treatment of metastatic pancreatic cancer when compared to gemcitabine monotherapy (overall survival 11.1 month in the FOLFIRINOX group versus 6.8 months in the gemcitabine group - hazard ratio for death, 0.57; 95% confidence interval [CI], 0.45 to 0.73; P<0.001). However, this increased activity came at the cost of higher treatment-related side effects.

Recently, the NAPOLI-1 trial yielded promising results for the combination of liposomal irinotecan (nal-Iri) in combination with 5-FU/folinic acid (FA) in patients pretreated with a gemcitabine-based first-line regimen.

Finally, Phase II data show promising efficacy and favorable toxicity with conventional FOLFIRI.3 in the treatment of advanced pancreatic cancer.

Furthermore, studies in colorectal cancer demonstrated a comparable efficacy and favorable toxicity when comparing conventional FOLFOXIRI (+ bevacizumab) and sequential FOLFOXIRI (alternating FOLFOX and FOLFIRI) in combination with bevacizumab.

With these novel treatment options at hand it is imperative to define the optimal first-line treatment modality in order to allow for an optimized treatment sequence to ensure for maximal success with acceptable toxicity.

Conditions

Metastatic Pancreatic Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

A: Gemcitabine/nab-Paclitaxel (Standard)

Nab-paclitaxel 125 mg/m2, i.v. infusion over about 30 minutes followed by Gemcitabine 1000 mg/m2 as a 30-minute i.v. infusion on D1, D8, D15 of a 28-day cycle.

Treatment is given until disease progression or the occurrence of unacceptable toxicity.

Group Type: ACTIVE_COMPARATOR

Gemcitabine

Intervention Type: DRUG

Arm A

Nab-paclitaxel

Intervention Type: DRUG

Arm A

B: NAPOLI regimen

On Day 1 of a 14-day cycle:

Liposomal irinotecan 80 mg/m2 i.v. over about 90 minutes followed by Folinic acid 400 mg/m2 i.v. over about 30 minutes followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)

Treatment is given until disease progression or the occurrence of unacceptable toxicity.

Group Type: EXPERIMENTAL

5-FU

Intervention Type: DRUG

Arm B Arm C

Irinotecan Liposomal Injection

Intervention Type: DRUG

Arm B Arm C

C: seq-NAPOLI-FOLFOX

The NAPOLI regimen and the mFOLFOX6 regimen are applied in an alternating fashion, starting with the NAPOLI regimen.

NAPOLI:

On Day 1 of a 14-day cycle:

Liposomal irinotecan 80 mg/m2 i.v. over about 90 minutes followed by Folinic acid 400 mg/m2 i.v. over about 30 minutes followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)

mFOLFOX6:

On Day 1 of a 14-day cycle:

Oxaliplatin 85 mg/m2 as i.v. infusion over 2 to 6 hours according to local practice at trial site Folinic acid 400 mg/m2 as i.v. infusion; infusion duration according to local practice at trial site followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)

Treatment is given until disease progression or the occurrence of unacceptable toxicity.

Group Type: EXPERIMENTAL

5-FU

Intervention Type: DRUG

Arm B Arm C

Irinotecan Liposomal Injection

Intervention Type: DRUG

Arm B Arm C

Oxaliplatin

Intervention Type: DRUG

Arm C

Interventions

Gemcitabine

Arm A

Intervention Type: DRUG

Nab-paclitaxel

Arm A

Intervention Type: DRUG

5-FU

Arm B Arm C

Intervention Type: DRUG

Irinotecan Liposomal Injection

Arm B Arm C

Intervention Type: DRUG

Oxaliplatin

Arm C

Intervention Type: DRUG

Other Intervention Names

Gemzar; Abraxane; 5-Fluoruracil; Onivyde; Trans-l-diaminocyclohexanoxalatoplatin

Eligibility Criteria

Inclusion Criteria

• Adult patients ≥ 18 years of age and ≤ 75 years
• Histologically (not cytologically) confirmed diagnosis of metastatic pancreatic ductal adenocarcinoma (PDAC) [Stage IV according to UICC TNM edition 8 of 201622: each T, each N, M1]
• No option for surgical resection or radiation in curative intent
• At least one unidimensionally measurable tumor lesion (according to RECIST 1.1)
• ECOG performance status 0 - 1
• Life expectancy at least 3 months
• Adequate hepatic, renal and bone marrow function, defined as:
• Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
• Haemoglobin ≥ 9 g/dL
• Thrombocytes ≥ 100 x 109/L
• Total bilirubin ≤ 1.5 x ULN. Patients with a biliary stent may be included provided that bilirubin level after stent insertion decreased to ≤ 1.5 x ULN and there is no cholangitis.
• AST/GOT and/or ALT/GPT ≤ 2.5 x ULN or in case of liver metastasis ≤ 5 x ULN)
• Serum creatinine within normal limits or creatinine clearance ≥ 60 mL/min/1.73 m2 as calculated by CKD-EPI formula for patients with serum creatinine levels above or below the institutional normal value.
• Females of childbearing potential (FCBP) must have a negative highly sensitive serum pregnancy test within 7 days of the first administration of study treatment and they must agree to undergo a further pregnancy tests at monthly intervals and at the end of treatment visit and FCBP must either agree to use and be able to take highly effective contraceptive birth control methods (Pearl Index < 1) during the course of the study and for at least 1 month after last administration of study treatment. Complete sexual abstinence is acceptable as a highly effective contraceptive method only if the subject is refraining from heterosexual intercourse during the entire study treatment and at least one month after the discontinuation of study treatment and the reliability of sexual abstinence is in line with the preferred and usual lifestyle of the subject. A female subject following menarche is considered to be of childbearing potential unless she is naturally amenorrhoeic for ≥ 1 year without an alternative medical reason, or unless she is permanently sterile.
• Males must agree to use condoms during the course of the trial and for at least 6 months after last administration of study drugs or practice complete abstinence from heterosexual intercourse.
• Signed and dated informed consent before the start of any specific protocol procedures
• Patient's legal capacity to consent to study participation

Exclusion Criteria

• Locally advanced PDAC without metastasis
• Symptomatic/clinically significant ascites (expected indication for repeated paracentesis)
• Known metastatic disease to the brain. Brain imaging is required in symptomatic patients to rule out brain metastases, but is not required in asymptomatic patients.
• Previous palliative chemotherapy or other palliative systemic tumor therapy for metastatic disease of PDAC
• Previous gemcitabine or 5-FU based treatment with exception of gemcitabine/fluoropyrimidine based treatment applied in the neoadjuvant or adjuvant setting (before/after potential curative R0 or R1 resection) and if the neoadjuvant/adjuvant chemotherapy was terminated at least 6 months before randomization
• Previous radiotherapy of PDAC with exception of radiotherapy in the context of a neoadjuvant or adjuvant treatment setting that was terminated at least 6 months before randomization
• Any major surgery within the last 4 weeks before randomization
• Clinically significant decrease in performance status within 2 weeks of intended first administration of study medication (by medical history)
• Severe tumor-related cachexia and/or known weight loss > 15% within one month before study enrollment
• Pre-existing polyneuropathy ≥ grade 2 according to CTCAE version 4.03
• Gastrointestinal disorders that might interfere with the absorption of the study drug and gastrointestinal disorders with diarrhoea as a major symptom (e.g. Crohn's disease, malabsorption), and chronic diarrhoea of any aetiology CTCAE version 4.03 grade ≥ 2
• Any other severe concomitant disease or disorder, which could influence patient's ability to participate in the study and his/her safety during the study or interfere with interpretation of study results e.g. active infection, uncontrolled hypertension, clinically significant cardiovascular disease e.g. cerebrovascular accident (≤ 6 months before study start), myocardial infarction (≤ 6 months before study start), unstable angina, heart failure ≥ NYHA functional classification system grade 2, severe cardiac arrhythmia requiring medication, metabolic dysfunction, severe renal disorder.
• Any other malignancies than PDAC within the last 5 years before study start, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer
• Hypersensitivity to the study drugs or to any of the excipients or to compounds with similar chemical or biologic composition
• Use of strong CYP3A4 inhibitors (CYP3A4 inhibitors have to be discontinued at least one week prior to start of study treatment).

Use or strong UGT1A1 inhibitors or strong CYP3A4 inducers unless there are no therapeutic alternatives.

• Known glucuronidation deficiency (Gilbert's syndrome) (specific screening not required)
• Known DPD deficiency (specific screening not required)
• Requirement for concomitant antiviral treatment with sorivudine or brivudine
• Continuing abuse of alcohol, drugs, or medical drugs
• Pregnant or breast-feeding females or FCBPs unable to either perform highly effective contraceptive measures or practice complete abstinence from heterosexual intercourse
• Current or recent (within 4 weeks prior to randomization) treatment with an investigational drug or participation in an investigational clinical trial

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ludwig-Maximilians - University of Munich

OTHER

Sponsor Role: lead

Responsible Party

PD Dr. med. Volker Heinemann

Professor of Medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Volker Heinemann, MD

Role: PRINCIPAL_INVESTIGATOR

LMU Munich

Locations

Klinikum der Universitaet Muenchen - Campus Grosshadern

Munich, , Germany

Countries

Germany

Other Identifiers

2017-003496-54

Identifier Type: -

Identifier Source: org_study_id